Bristol-Myers Squibb SVP Sells $997,800 in Stock (BMY)
Bristol-Myers Squibb (NYSE:BMY) SVP Autenried Paul Von unloaded 20,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $49.89, for a total value of $997,800.00. Following the sale, the senior vice president now directly owns 37,523 shares of the company’s stock, valued at approximately $1,872,022. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on BMY shares. Analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Friday, July 25th. They now have a $52.00 price target on the stock. Finally, analysts at MKM Partners raised their price target on shares of Bristol-Myers Squibb from $29.00 to $34.00 in a research note on Friday, July 25th. They now have a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $51.81.
Bristol-Myers Squibb (NYSE:BMY) traded down 0.40% during mid-day trading on Thursday, hitting $49.8401. The stock had a trading volume of 878,874 shares. Bristol-Myers Squibb has a 52 week low of $41.11 and a 52 week high of $57.49. The stock’s 50-day moving average is $49.2 and its 200-day moving average is $50.41. The company has a market cap of $82.630 billion and a P/E ratio of 31.08.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 24th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter in the prior year, the company posted $0.44 earnings per share. The company’s quarterly revenue was down 3.9% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post $1.81 earnings per share for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with Analyst Ratings Network's FREE daily email newsletter.